pravastatin has been researched along with niacin in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 14 (42.42) | 18.2507 |
| 2000's | 11 (33.33) | 29.6817 |
| 2010's | 7 (21.21) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Imai, K; Kobayashi, D; Nezu, J; Nozawa, T; Tamai, I; Tsuji, A | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Brown, WV; Karmally, W; Smith, DA | 1 |
| Cooper, ME; Jerums, G; Panagiotopoulos, S; Sinha, A; Tsalamandris, C | 1 |
| Harris, WS; Nelson, J; O'Keefe, JH; Windsor, SL | 1 |
| Higashida, H; Maeda, H; Ogihara, T; Sai, Y; Takanaga, H; Tamai, I; Tsuji, A | 1 |
| Gibson, CM; Pasternak, RC; Rosner, B; Sacks, FM; Stone, PH | 1 |
| Connelly, PW; Davignon, J; Gagné, C; Hayden, MR; Hegele, R; Lupien, PJ; McPherson, R; Montigny, M; Roederer, G; Tan, MH | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Grundy, SM; Mostaza, JM; Schulz, I; Vega, GL | 1 |
| Fonseca, VA; Gardner, SF; Granberry, MC; Marx, MA; Skelton, DR; White, LM | 1 |
| Grundy, SM | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Sinzinger, H | 1 |
| Applegate, W; Crouse, J; Davis, KB; Egan, DA; Elam, MB; Garg, R; Herd, JA; Hunninghake, DB; Kostis, JB; Pettinger, MB; Probstfield, J; Sheps, DS; Waclawiw, MA; Wilt, TJ | 1 |
| Davis, KB; Egan, DA; Garg, R; Griffin, B; Pettinger, MB; Thomason, T; Waclawiw, MA | 1 |
| Agrawal, R; Arntz, HR; Fischer, F; Linderer, T; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W | 1 |
| Hsu, JC; Kashyap, ML; Sikand, G; Wong, ND | 1 |
| Applegate, WB; Crouse, JR; Davis, KB; Egan, D; Elam, MB; Garg, R; Herd, JA; Hunninghake, DB; Johnson, WC; Kennedy, JW; Kostis, JB; Sheps, DS | 1 |
| Agrawal, R; Arntz, HR; Fischer, F; Schnitzer, L; Schultheiss, HP; Stern, R; Wunderlich, W | 1 |
| Stein, EA | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Blazing, MA; Duvall, WL; Guyton, JR; Saxena, S | 1 |
| Lipton, AM; Lutjohann, D; Moore, C; Svetlik, D; Vega, GL; Von Bergmann, K; Weiner, MF | 1 |
| Baskin, F; Fang, X; Hynan, LS; Moore, CB; Rosenberg, RN; Vega, GL; Weiner, M | 1 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Charles, MA; Ishida, B; Kane, JP; Malloy, MJ; Pan, J; Shilian, P; Wu, X | 1 |
5 review(s) available for pravastatin and niacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
Topics: Cholesterol, HDL; Cholesterol, VLDL; Clinical Trials as Topic; Consensus Development Conferences as Topic; Coronary Disease; Drug Therapy, Combination; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Triglycerides; Weight Loss | 1998 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
14 trial(s) available for pravastatin and niacin
| Article | Year |
|---|---|
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Male; Middle Aged; Niacin; Pravastatin; Treatment Outcome; Triglycerides | 1994 |
Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia.
Topics: Adult; Apolipoprotein A-I; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Eating; Humans; Hypertriglyceridemia; Lipids; Magnesium; Niacin; Pravastatin; Risk Factors; Triglycerides | 1995 |
Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Harvard Atherosclerosis Reversibility Project (HARP) Group.
Topics: Anticholesteremic Agents; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Coronary Angiography; Coronary Artery Disease; Female; Follow-Up Studies; Gemfibrozil; Humans; Lipids; Male; Middle Aged; Niacin; Pravastatin; Treatment Outcome | 1994 |
Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Combinations; Female; Flushing; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Nausea; Niacin; Placebos; Pravastatin; Single-Blind Method; Triglycerides | 1994 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Humans; Hyperlipidemias; Middle Aged; Niacin; Pravastatin; Risk Factors; Triglycerides | 1997 |
Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fructosamine; Humans; Hypercholesterolemia; Lipoprotein(a); Male; Middle Aged; Niacin; Pravastatin; Prospective Studies | 1997 |
Compliance to multiple interventions in a high risk population.
Topics: Adult; Aged; Anticholesteremic Agents; Anticoagulants; Antioxidants; Aspirin; Data Interpretation, Statistical; Double-Blind Method; Female; Humans; Male; Niacin; Patient Compliance; Peripheral Vascular Diseases; Placebos; Platelet Aggregation Inhibitors; Pravastatin; Time Factors; Warfarin | 1999 |
[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Coronary Disease; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Prospective Studies; Treatment Outcome | 1999 |
Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Antioxidants; Arteriosclerosis; Aspirin; Cholesterol, LDL; Feasibility Studies; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Niacin; Platelet Aggregation Inhibitors; Pravastatin; Risk Factors; Self Medication; Time Factors; Treatment Outcome; Triglycerides; Vitamins; Warfarin | 2000 |
Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Chemoprevention; Chi-Square Distribution; Cholesterol, LDL; Cholestyramine Resin; Confidence Intervals; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Drug Combinations; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Niacin; Odds Ratio; Peripheral Vascular Diseases; Pravastatin; Regression Analysis; Statistics, Nonparametric; Stroke; Survival Rate; Treatment Outcome | 2000 |
Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease.
Topics: Aged; Alzheimer Disease; Brain; Cholesterol 24-Hydroxylase; Female; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Simvastatin; Steroid Hydroxylases; Treatment Outcome | 2003 |
Correlation of statin-increased platelet APP ratios and reduced blood lipids in AD patients.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Blood Platelets; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pravastatin; Protein Processing, Post-Translational; Simvastatin; Single-Blind Method | 2003 |
Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Simvastatin | 2011 |
14 other study(ies) available for pravastatin and niacin
| Article | Year |
|---|---|
Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane.
Topics: Biological Transport; Carbon Radioisotopes; Cell Membrane; Cells, Cultured; Estrone; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; Intestine, Small; Organic Anion Transporters; Pravastatin; Radiopharmaceuticals; Time Factors; Tritium | 2003 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Treating hyperlipidemia, Part III: Drug therapy.
Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Pravastatin | 1987 |
Participation of a proton-cotransporter, MCT1, in the intestinal transport of monocarboxylic acids.
Topics: Animals; Biological Transport; Carboxylic Acids; Carrier Proteins; CHO Cells; Cricetinae; Female; Hydrogen-Ion Concentration; Ibuprofen; Intestinal Mucosa; Lactates; Mandelic Acids; Membrane Proteins; Monocarboxylic Acid Transporters; Niacin; Oocytes; Pravastatin; Propionates; Protons; Rabbits; Recombinant Proteins; RNA, Complementary; RNA, Messenger; Stereoisomerism; Transcription, Genetic; Transfection; Valproic Acid; Xenopus laevis | 1995 |
Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study.
Topics: Adult; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Niacin; Peripheral Vascular Diseases; Pilot Projects; Pravastatin; Randomized Controlled Trials as Topic; Research Design | 1999 |
Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Dietary Services; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Medical Records; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Time Factors; Treatment Refusal; Triglycerides | 2000 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |
Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Drug Therapy, Combination; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Risk Factors; Treatment Outcome | 2002 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |